Aardvark Therapeutics, Inc. — Director's Dealing 2025

Feb 13, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aardvark Therapeutics, Inc. (AARD)
CIK: 0001774857
Period of Report: 2025-02-12

Reporting Person: Vickers Venture Fund VI Pte Ltd (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (1637411)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (413491)		Indirect

Footnotes

F1: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") is convertible into shares of common stock of the Issuer ("Common Stock") at the holder's election on an 8.474-for-1 basis and has no expiration date. All shares of Series A Convertible Preferred Stock will automatically convert on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P.. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI.

F3: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

F4: The Series B Convertible Preferred Stock of the Issuer is convertible into shares of Common Stock at the holder's election on an 8.474-for-1 basis and has no expiration date. All shares of Series B Convertible Preferred Stock will automatically convert on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.